TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01162824

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine
Description: Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.

Intervention type: DRUG
Group type: OTHER
Intervention: Acetylcholine
Description: Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.

Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).

Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
Study: NCT01825512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Deferiprone 80 mg/mL oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferasirox
Description: Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
Study: NCT02091362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered as background therapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Administered as background therapy.
Study: NCT04444986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVIR 200 MG FT
Description: FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FAVIR 200 MG FT
Description: FAVICOVIR containing 200 mg favipiravir manufactured by Kocak, Turkey.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 mg FT
Description: AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVIGAN 200 mg FT
Description: AVIGAN containing 200 mg favipiravir manufactured by Toyama, Japan
Study: NCT02815696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
Study: NCT03407469

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Questionnaires completed at the time participant joins this study and then about 30 days, 3 months, 6 months, and 12 months after that. Questionnaires will be about quality of life and experiences with treatment for venous thromboembolism (VTE). It should take less than 10 minutes to complete the questionnaires each time.
Study: NCT02108327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical blade
Description: Using surgical blade all the time of surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: electrocautery
Description: Using electrocautery all the time except at skin incision
Study: NCT03063723

Intervention type: DRUG
Intervention: Ledipasvir-Sofosbuvir
Description: 8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks

Intervention type: DRUG
Intervention: Daclatasvir-Sofosbuvir
Description: 7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
Study: NCT00761384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-ibritumomab
Description: 90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
Study: NCT03680196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medication Botulinum A injection.
Description: In cerebral palsy patients, Botulinum toxin within the allowable dose of 16 U / kg per body weight will injected into both adductor longus, adductor magnus muscle at 3 U / kg, adductor brevis, and gracilis muscle at a dose of 1 U / kg.
Study: NCT03972462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12G Gel 0.2%
Description: Period 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamune® 2 mg tablet
Description: Period 2
Study: NCT00718575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose/Ischemic Preconditioning Pre-treatment
Description: A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
Study: NCT01550406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tachocomb
Description: A kind of Mesh:~ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyglycolic acid (PGA) (Neoveil)
Description: Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
Study: NCT00419211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Tailored exercise program
Study: NCT01811589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thomale-Guide
Description: Ventricular catheter placement with the Thomale-Guide instrument

Intervention type: OTHER
Group type: OTHER
Intervention: Free-hand
Description: Ventricular catheter placement without a guidance (free-hand)
Study: NCT02295696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMMA
Description: Consultations using dialogue tools
Study: NCT01232504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhGM-CSF group
Description: subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF+rhGM-CSF group
Description: a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhG-CSF group
Description: subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count \[ANC\] \> 1.5×10(9)/L for 2 consecutive days).
Study: NCT03208660

Intervention type: DRUG
Intervention: Fycompa
Description: Oral suspension
Study: NCT00423982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin-combination therapy
Description: Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy
Description: Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
Study: NCT04351399

Intervention type: OTHER
Intervention: questionnaire assesment
Description: The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine
Study: NCT03832322

Intervention type: PROCEDURE
Intervention: Water exchange colonoscopy
Description: During back-to-back colonoscopy, the first examination was completed with water exchange during insertion and CO2 insufflation during withdrawal. The second examination was completed with CO2 insufflation during both the insertion and withdrawal.

Intervention type: PROCEDURE
Intervention: CO2 insufflation colonoscopy
Description: During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.

Intervention type: PROCEDURE
Intervention: CO2 insufflation colonoscopy
Description: During back-to-back colonoscopy, the first examination was completed with CO2 insufflation during both the insertion and withdrawal. The second examination was also completed with CO2 insufflation during both the insertion and withdrawal.
Study: NCT02574884

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample (act specific of blood withdrawal for the study)
Description: Specific intervention : blood sample (3x7 ml in total)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample (act specific of blood withdrawal for the study)
Description: Specific intervention : blood sample (3x7 ml in total)
Study: NCT01255176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal rebalancing
Description: In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
Study: NCT00799227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
Study: NCT01899508

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training Session
Description: The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D viewer with iPod Touch/iPhone (or similar smartphone)
Description: The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
Study: NCT01889264

Intervention type: OTHER
Intervention: Observational
Description: Observational, Translational non-treatment study
Study: NCT01606176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-1000-02
Description: Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
Study: NCT04022629

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Washout Only
Description: To wash out the shoulder joint with a sterile solution through an arthroscope (keyhole surgery) under a general anaesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Bankart Repair
Description: To repair the torn glenoid labrum in the shoulder, using key-hole (arthroscopic) surgery techniques under general anaesthetic. The Bankart technique is well described and will be performed using suture anchors.
Study: NCT04322266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904
Description: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904
Description: Amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0608
Description: Losartan potassium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0608
Description: Losartan potassium
Study: NCT02845115

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional implantation
Description: Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.~MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optimized implantation with laser velocimetry
Study: NCT02365324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Education Family Fitness Program (PE-FFP)
Description: The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family Fitness Program (FFP)
Description: The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns \[i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010\] and SCT variables.
Study: NCT03212209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Fixed Pressure
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP Fixed Pressure
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Fixed Pressure
Description: Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
Study: NCT01569724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose tolerance test (OGTT)
Description: patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
Study: NCT03088332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic gastroplasty
Description: Vertical endoscopic gastroplasty
Study: NCT00686699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study: NCT02589756

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The fatty fish group
Description: At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The fatty fish group
Description: At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (\~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
Study: NCT04303091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity for Advanced Cancer Treatment (PAACT)
Description: 12-week physical activity intervention. 60 minute group-based exercise classes held once per week. Home-based exercise recommendations provided weekly along with basic take-home exercise equipment. Optional palliative care consultations offered.
Study: NCT04888182

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: intervention
Description: a protein intake of ≥25 E%. An oral nutritional supplement (containing 1570 kJ/100 g and 92 g protein/100 g. Atpro 200) was used as supplement to the patients' habitual diet.
Study: NCT03092622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training intervention as described earlier.
Study: NCT02291328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Brassica
Description: Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Brassica
Description: Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.